BMT Tandem "Scientific" Meeting
Harbor Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Daniel R. Couriel, MD, MS
and
Robert B. Levy, PhD
Disclosures:
D. R. Couriel,
Therakos, Inc, None:
Research Funding
Merck, Inc, None:
Advisory Board
R. B. Levy,
Allergan, Consulting:
Consultancy
Serpin Pharmaceutical, Independent contractor:
Research Funding
Third Party Invariant Natural Killer T Cells Protect from Lethal Graft-Versus-Host Disease through Donor CD4+CD25+FoxP3+ Regulatory T Cells
Dominik Schneidawind, MD, Stanford University;
Antonio Pierini, MD, Stanford University;
Jeanette Baker, PhD, Stanford University;
Corina Buechele, MD, Stanford University;
Richard Luong, BVSC, DACVP, Stanford University;
Everett Meyer, MD, PhD, Stanford University;
Robert Negrin, MD, Stanford University
Siglec-G Expression on Donor T Cells Controls Severity of Gvhd
Tomomi Toubai, M.D., PhD, University of Michigan Comprehensive Cancer Center;
Corinne Rossi, University of Michigan Comprehensive Cancer Center;
Guoqing Hou, Ph.D, University of Michigan Comprehensive Cancer Center;
Katherine Oravecz-Wilson, University of Michigan Comprehensive Cancer Center;
Chen Liu, University of Florida College of Medicine;
Nathan Mathewson, University of Michigan Comprehensive Cancer Center;
Yaping Sun, Ph.D., University of Michigan Comprehensive Cancer Center;
Julia Wu, University of Michigan Comprehensive Cancer Center;
Pang Zheng, Center for Cancer and Immunology Research, Children’s National Medical Center;
Yang Liu, Center for Cancer and Immunology Research, Children’s National Medical Center;
Sung Won Choi, M.D., University of Michigan;
Pavan Reddy, MD, University of Michigan Comprehensive Cancer Center
Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation
Kirsten M. Williams, MD, CNMC/National Cancer Institute, NIH;
Guang-Shing Cheng, MD, University of Washington School of Medicine;
Iskra Pusic, MD, Washington University Medical Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
Linda J. Burns, MD, National Marrow Donor Program;
Vincent T. Ho, MD, Dana-Farber Cancer Institute;
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Jeanne Palmer, MD, Mayo Clinic Arizona;
Laura Johnston, MD, Stanford University Medical Center;
Sebastian Mayer, MD, Weill Cornell Medical Center;
David A. Jacobsohn, MD, Children's National Medical Center;
Paul J. Martin, MD, Fred Hutchinson Cancer Research Center;
Barry E. Storer, PhD, Fred Hutchinson Cancer Research Center;
Yoshihiro Inamoto, MD PhD, National Cancer Center Hospital;
Xiaoyu Chai, MS, Fred Hutchinson Cancer Research Center;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center
A Biomarker Panel for Chronic Graft-Versus-Host Disease
Jeffrey Yu, Indiana University School of Medicine;
Barry E. Storer, PhD, Fred Hutchinson Cancer Research Center;
Etienne Daguindau, MD, Indiana University;
Qing Zhang, Fred Hutchinson Cancer Research Center;
Phillip R Gafken, PhD, Fred Hutchinson Cancer Research Center;
Yuko Ogata, PhD, Fred Hutchinson Cancer Research Center;
Paul J. Martin, MD, Fred Hutchinson Cancer Research Center;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center;
John A. Hansen, MD, Fred Hutchinson Cancer Research Center;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Sophie Paczesny, MD, PhD, Indiana University School of Medicine
Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft-Versus-Leukemia
Jilu Zhang, PhD, Indiana University School of Medicine;
Benjamin Ulrich, Indiana University School of Medicine;
Abdulraouf Ramadan, PhD, Indiana University School of Medicine;
Hanenberg Helmut, MD, Indiana University School of Medicine;
McKenzie Andrew, MD, PhD, Medical Research Council Laboratory of Molecular Biology;
Isao Tawara, M.D., Ph.D., Mie University Hospital;
Sophie Paczesny, MD, PhD, Indiana University
Updated Results of the Mayo Clinic Risk Adapted Algorithm for Peripheral Blood Stem Cell Mobilization Utilizing G-CSF and Plerixafor
Raina M Ferzoco, MD, Mayo Clinic;
Ivana N Micallef, MD, Mayo Clinic;
Jeffrey Winters, M.D., Mayo Clinic;
Stephen Ansell, MD, PhD, Mayo Clinic;
Francis Buadi, MD, Mayo Clinic;
David Dingli, MD, Mayo Clinic;
Angela Dispenzieri, MD, Mayo Clinic;
Dennis A. Gastineau, MD, Mayo Clinic;
Morie Gertz, MD, Mayo Clinic;
Shahrukh Hashmi, MD, MPH, Mayo Clinic Rochester;
Suzanne Hayman, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
David J Inwards, MD, Mayo Clinic;
Patrick B Johnston, MD, PhD, Mayo Clinic;
Prashant Kapoor, MD, Mayo Clinic;
Martha Lacy, MD, Mayo Clinic;
Mark R. Litzow, MD, Mayo Clinic Rochester;
Mrinal Patnaik, MBBS, Mayo Clinic;
Luis F Porrata, MD, Mayo Clinic;
Shaji Kumar, MD, Mayo Clinic
![[Visit Client Website]](images/banner.gif)